Denali Therapeutics Inc. (DNLI) Quick Ratio
- Quick ratio · latest quarter: Value 7.93×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 7.93× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $714.40M ÷ $90.08M ≈ 7.93× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 714.40M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 90.08M USD | Liabilities, Current |
| Cash and equivalents | 201.53M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 508.94M USD | Marketable Securities, Current |
| Customer receivables | 3.93M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 4.14M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $714.40M | $90.08M | $201.53M | $508.94M | $3.93M | $4.14M | 7.93× |
| 2026-03-31 | (m) | $110.16M | $387.63M | $600.06M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $98.35M | $205.33M | $662.55M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $90.15M | $90.96M | $757.24M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $91.06M | $141.21M | $757.75M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $91.88M | $56.95M | $760.98M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $102.21M | $174.96M | $657.37M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $87.09M | $90.64M | $745.92M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $74.53M | $74.68M | $821.37M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $82.58M | $60.57M | $876.29M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $77.98M | $127.11M | $907.40M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $71.18M | $148.01M | $961.25M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $69.36M | $131.97M | $1.06B | (m) | (m) | (m) |
| 2023-03-31 | (m) | $391.08M | $68.13M | $1.22B | (m) | (m) | (m) |
| 2022-12-31 | (m) | $363.92M | $218.04M | $1.12B | (m) | (m) | (m) |
| 2022-09-30 | (m) | $360.67M | $118.61M | $987.44M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $348.16M | $155.09M | $913.58M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $341.24M | $104.95M | $852.57M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $378.25M | $293.48M | $571.93M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $54.25M | $394.55M | $644.62M | (m) | (m) | (m) |
| 2021-06-30 | $1.32B | $51.41M | $485.68M | $823.25M | $15.22M | (m) | 25.76× |
| 2021-03-31 | (m) | $54.61M | $435.32M | $977.83M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $71.70M | $507.14M | $962.55M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $105.41M | $351.05M | $610.15M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $58.46M | $137.18M | $412.40M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $47.63M | $207.54M | $379.71M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $45.34M | $79.45M | $335.91M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $46.69M | $82.67M | $396.72M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $46.55M | $62.94M | $415.67M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $43.24M | $39.66M | $445.82M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $32.79M | $77.12M | $387.17M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $31.62M | $43.65M | $331.31M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $31.01M | $33.09M | $339.50M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $17.17M | $44.00M | $329.40M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $14.16M | $218.38M | $187.85M | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $36.27M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $41.31M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $36.75M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $39.85M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |